Noble Financial keeps USD 12.00 target for Ocugen stock

Published on 10/24/2026 at 18:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ocugen reports third-quarter results on November 4, 2026. Ocugen stock costs EUR 0.66 on October 24, 2026, down 9.59 percent versus the German close.

Analyst target and earnings date

Noble Financial reiterated a Buy rating and a USD 12.00 target on September 29, 2026.
Ocugen reported USD 1.49 million in second-quarter 2026 revenue and a USD 0.07 adjusted loss per share.
Ocugen stock costs EUR 0.66 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST, down 9.59 percent versus the German close of October 23, 2026.
Ocugen plans to report third-quarter 2026 results on November 4, 2026.

OCGN, US67577C1053, Illustration mit AI erstellt.

Ocugen (ISIN US67577C1053) has a USD 12.00 price target from Noble Financial, which reiterated its Buy rating on September 29, 2026, according to The Globe and Mail. Ocugen will report third-quarter 2026 results on November 4, 2026, a date announced in a company release carried by MarketScreener. The stock was at EUR 0.66 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST, down 9.59 percent versus the German close of EUR 0.73 on October 23, 2026.

Revenue reached USD 1.49 million

Ocugen's second-quarter 2026 revenue was USD 1.49 million, while adjusted earnings per share came to a loss of USD 0.07. The figures were reported by MarketBeat, which also said revenue exceeded the USD 0.89 million consensus estimate while the loss was wider than the expected USD 0.05 per share.

Price remains below its yearly high

Ocugen's Nasdaq listing closed at USD 0.74 on October 23, 2026. Its 52-week range was USD 0.73 to USD 2.73 as of that date, putting the latest US quotation near its yearly low and 72.89 percent below the high. Market capitalization stood at USD 250.8 million, and volume reached 8,477,078 shares on October 23, 2026.

November 4 brings the next test

The November 4 release is scheduled to include a business update and third-quarter 2026 financial results. Ocugen is developing gene therapies for blindness diseases, including programs for retinitis pigmentosa, Stargardt disease and geographic atrophy, according to its investor-relations profile.

Target remains far above the market

Noble Financial's USD 12.00 target is denominated in US dollars and therefore is not directly compared with the EUR 0.66 German quotation. The target nevertheless sits well above the latest Nasdaq price of USD 0.74, while the company's second-quarter revenue and continuing development costs keep the November report central to the valuation discussion.

Trading position on October 24

The stock's EUR 0.66 Lang & Schwarz quotation on October 24, 2026 at 1:04 p.m. CEST was 9.59 percent below the German close of EUR 0.73 from October 23, 2026. The further course of trading is shown by the continuously updated real-time quote of Ocugen stock.